<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0603245033
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Rina Extra
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        DESLORATADINE,PSEUDOEPHEDRINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        2.5,120
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        modified-release tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        OTC
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        35.00
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="DAR ALDAWA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            DAR ALDAWA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            DAR Al DAWA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        R01BA52
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Rina</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>Extra</strong><strong><sup> </sup></strong>extended release tablets is a prescription medicine that contains the medicines Desloratadine (an antihistamine) and Pseudoephedrine (a nasal decongestant). <strong>Rina</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>Extra</strong><strong><sup> </sup></strong>is used to help control the symptoms of seasonal allergic rhinitis (sneezing, stuffy nose, runny nose and itching of the nose) in adults and children 12 years and older.</p><p>&nbsp;</p><p><strong>Rina</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>Extra</strong><strong><sup> </sup></strong>is not for children under 12 years of age.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Rina</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>Extra if you:</strong></p><p><strong>&nbsp;</strong></p><ul><li>are allergic to Desloratadine or Pseudoephedrine sulfate or any of the ingredients in <strong>Rina Extra</strong><strong><sup>&reg;</sup></strong><strong> </strong>tablets (listed in section 6).<strong> </strong>&nbsp;</li><li>are allergic to loratadine</li><li>have narrow-angle glaucoma</li><li>have problems with urination (urinary retention)</li><li>take a monoamine oxidase inhibitor (MAOI) medicine to treat depression, or if you stopped taking an MAOI medicine within the last 2 weeks. Ask your doctor or pharmacist if you are not sure if you take an MAOI medicine.</li><li>have severe high blood pressure</li><li>have severe heart disease</li></ul><p>Talk to your doctor before taking this medicine if you have any of these conditions.</p><p><strong>Warning and precautions </strong></p><p><strong>&nbsp;</strong></p><p>Before you take <strong>Rina</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>Extra</strong>, tell your doctor if you:</p><ul><li>have any of the conditions listed in the section &ldquo;<strong>Do not take Rina</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>Extra if you&rdquo;</strong></li><li>diabetes</li><li>hyperthyroidism</li><li>have prostate problems</li><li>have liver or kidney problems</li><li>have any other medical conditions</li><li>are pregnant or plan to become pregnant. It is not known if <strong>Rina</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>Extra</strong><strong> </strong>will harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant.</li><li>are breastfeeding or plan to breastfeed. <strong>Rina</strong><strong><sup>&reg;</sup></strong><strong> Extra</strong><strong><sup> </sup></strong><strong>can pass into your breast milk</strong>. Talk to your doctor about the best way to feed your baby if you take <strong>Rina</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>Extra</strong>.</li></ul><p>&nbsp;</p><p><strong>Children</strong></p><p><strong>Rina</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>Extra</strong><strong> </strong>is not for children under 12 years of age.</p><p><strong>Other medicines and Rina</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>Extra</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>Tell your doctor about all the medicines you take,<strong> </strong>including prescription and nonprescription medicines, vitamins and herbal supplements.</p><p><strong>Rina</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>Extra</strong><strong> </strong>may affect the way other medicines work, and other medicines may affect how <strong>Rina</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>Extra </strong>works. Especially tell your doctor if you take:</p><ul><li>Monoamine oxidase inhibitors (MAOIs). You should not use <strong>Rina</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>Extra</strong><strong> </strong>if you take an MAOI or within 2 weeks of stopping an MAOI.</li><li>methyldopa</li><li>reserpine</li><li>digitalis (Digoxin),</li><li>Ketoconazole&nbsp;</li><li>erythromycin</li><li>azithromycin</li><li>antihistamines</li><li>other decongestant medicines</li></ul><p>&nbsp;</p><p>Know the medicines you take. Keep a list of your medicines and show it to your doctor and pharmacist when you get a new medicine.</p><p>&nbsp;</p><p><strong>Pregnancy and breastfeeding</strong></p><p><strong>&nbsp;</strong></p><p>Before you take <strong>Rina</strong><strong><sup>&reg;</sup></strong><strong> Extra</strong>, tell your doctor if you:</p><p>are pregnant or plan to become pregnant. It is not known if <strong>Rina</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>Extra</strong><strong> </strong>will harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant.</p><p>are breastfeeding or plan to breastfeed. <strong>Rina</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>Extra</strong><strong> </strong><strong>can pass into your breast milk</strong>. Talk to your doctor about the best way to feed your baby if you take <strong>Rina</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>Extra</strong>.</p><p>&nbsp;</p><p><strong>Rina</strong><strong><sup>&reg;</sup></strong><strong> Extra contains Sodium</strong></p><p>This medicine contains less than 1 mmol sodium (23 mg), this is to say essentially &lsquo;sodium- free&rsquo;.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine as your doctor or pharmacist has told you.</p><p>Check with your doctor or pharmacist if you are not sure.</p><p>The recommended dose is 1 <strong>Rina</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>Extra</strong><strong> </strong>tablet 2 times a day (every 12 hours).</p><p><strong>Rina</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>Extra</strong><strong> </strong>can be taken with or without food.</p><p>Swallow <strong>Rina</strong><strong><sup>&reg;</sup> Extra<sup> </sup></strong>tablets whole. <strong>Do not break, crush, or chew</strong> <strong>Rina</strong><strong><sup>&reg;</sup> Extra<sup> </sup></strong>tablets before swallowing. If you cannot swallow <strong>Rina</strong><strong><sup>&reg;</sup> Extra </strong>whole, tell your doctor. You may need a different medicine.</p><p><strong>If you </strong><strong>forget</strong><strong> to take Rina</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>Extra</strong></p><p>Do not take a double dose to make up for a forgotten dose.</p><p>If you have any further questions on the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>Rina</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>Extra </strong>may cause serious side effects, including:</p><ul><li>&nbsp;Cardiovascular and central nervous system effects, such as</li></ul><p>o&nbsp;&nbsp; unable to sleep (insomnia)</p><p>o&nbsp;&nbsp; dizziness</p><p>o&nbsp;&nbsp; weakness</p><p>o&nbsp;&nbsp; tremor</p><p>o&nbsp;&nbsp; irregular heart beat</p><p>o&nbsp;&nbsp; seizure</p><p>o&nbsp;&nbsp; low blood pressure</p><ul><li>Increased sleepiness or tiredness can happen if you take more Desloratadine /Pseudoephedrine sulfate than your doctor prescribed to you.</li><li>Allergic reactions. Stop taking <strong>Rina</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>Extra</strong><strong> </strong>and call your doctor right away or get emergency help if you have any of these symptoms:</li></ul><p>o&nbsp;&nbsp; rash</p><p>o&nbsp;&nbsp; itching</p><p>o&nbsp;&nbsp; hives</p><p>o&nbsp;&nbsp; swelling of your lips, tongue, face, and throat</p><p>o&nbsp;&nbsp; shortness of breath or trouble breathing</p><ul><li>Severe skin reactions including signs and symptoms such as fever, reddening of the skin, or many small pimples</li></ul><p>&nbsp;</p><p>The most common side effects of Desloratadine and Pseudoephedrine sulfate combination include:</p><p>o&nbsp;&nbsp; unable to sleep (insomnia)</p><p>o&nbsp;&nbsp; sore throat</p><p>o&nbsp;&nbsp; headache</p><p>o&nbsp;&nbsp; dizziness</p><p>o&nbsp;&nbsp; dry mouth</p><p>o&nbsp;&nbsp; nausea</p><p>o&nbsp;&nbsp; tiredness</p><p>o&nbsp;&nbsp; loss of appetite</p><p>o&nbsp;&nbsp; sleepiness</p><p>&nbsp;</p><p>Tell your doctor if you have any side effect that bothers you or that does not go away.</p><p>These are not all of the possible side effects of <strong>Rina</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>Extra</strong>. For more information, ask your doctor or pharmacist.</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p><strong>&nbsp;</strong></p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor, health care provider or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep this medicine out of the sight and reach of children.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine after the expiry date which is stated on the carton. The expiry date refers to the last day of that month.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store below 30&deg;C.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Rina</strong><strong><sup>&reg;</sup></strong><strong> Extra</strong><strong> </strong>contains<strong> </strong>the active ingredients Desloratadine and Pseudoephedrine sulfate. Each extended release tablet contains 2.5 mg Desloratadine and 120 mg Pseudoephedrine sulfate.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>The other ingredients are:</strong> Maize starch, microcrystalline cellulose, disodium edetate, citric acid monohydrate, indigo carmine (E132), pregelatinized starch, stearic acid, hypromellose, povidone, colloidal anhydrous silica, and magnesium stearate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Rina® Extra extended-release tablet is a bilayer oval-shaped tablet with blue layer coded (C116) and white plain layer. 
Rina® Extra extended-release tablets are packed in aluminum blisters of 10. 
Rina® Extra is available in packs of 10 (1 blister per pack), 20 (2 blisters per pack), and in packs of 30 (3 blisters per pack).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Dar Al Dawa Development &amp; Investment Co. Ltd.</p><p>Prince Hashem Bin Al-Hussein Street.</p><p>Na&#39;ur - Amman - Jordan.</p><p>Tel. (+962 6) 57 27 132</p><p>Fax. (+962 6) 57 27 776</p><p>&nbsp;</p><p><strong>To report any side effects:</strong></p><p><strong>&nbsp;</strong></p><p><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Jordan</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:558px"><tbody><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Jordan Food and Drug Administration</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Phone: +962 6 5632000</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Website: www.jfda.jo</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;reporting link&nbsp; https://primaryreporting.who-umc.org/jo</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Email: jpc@jfda.jo</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Saudi Arabia</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:558px"><tbody><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC):</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Centre: 19999</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: <u>https://</u><u>ade.sfda.gov.sa/</u></p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; United Arab Emirates</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:558px"><tbody><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pharmacovigilance and Medical Device Section</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Drug Department</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UAE Ministry of Health &amp; Prevention</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hotline: 80011111</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Email: pv@mohap.gov.ae</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; P.O. Box: 1853 Dubai UAE</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Sudan</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:558px"><tbody><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; National Medicines and Poisons Board (NMPB)</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fax: + 249 183522263</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: info@nmpb.gov.sd</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website : www.nmpb.gov.sd</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other countries</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:558px"><tbody><tr><td style="vertical-align:top"><p>&minus; Please contact the relevant competent authority.</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                01/2023
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">أقراص<strong> رينا اكسترا </strong>هي أقراص طويلة المفعول<strong> </strong>تصرف بوصفة طبية وتحتوي على ديسلوراتادين (دواء مضاد للهيستامين) وسودوإفدرين (دواء مضاد لاحتقان الأنف). يستخدم <strong>رينا اكسترا </strong>للمساعدة في السيطرة على أعراض التهاب الأنف التحسسي الموسمي (العطاس، انسداد الأنف، سيلان الأنف والحكة في الأنف) وذلك في البالغين والأطفال 12 عامًا فأكثر.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">لا يستعمل <strong>رينا اكسترا </strong>للأطفال دون سن 12 عامًا.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>موانع تناول </strong><strong>رينا اكسترا</strong><strong>:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><ul dir="rtl"><li>&nbsp;إن كان لديك حساسية تجاه ديسلوراتادين أو سودوإفدرين سلفات أو أي من مكونات أقراص <strong>رينا اكسترا </strong>(انظر القسم 6).</li><li>&nbsp;إن كان لديك حساسية تجاه لوراتادين</li><li>&nbsp;إن كان لديك ارتفاع ضغط العين ضيق الزاوية (جلوكوما)</li><li>إن كان لديك مشاكل في التبول (احتباس البول)</li><li>إذا كنت تتناول مثبط الأوكسيداز أحادي الأمين (MAOI) دواء لعلاج الاكتئاب، أو في حال توقفت عن تناول هذا الدواء خلال الأسبوعين الماضيين. اسأل طبيبك أو الصيدلي في حال لم تكن متأكدًا إن كنت تتناول دواء مثبط الأوكسيداز أحادي الأمين (MAOI) ام لا.</li><li>إن كان لديك ارتفاع شديد في ضغط الدم</li><li>&nbsp;إن كان لديك مرض شديد في القلب</li></ul><p dir="RTL">تحدث مع طبيبك قبل تناول هذا الدواء إذا كان لديك أي من الحالات المذكورة أعلاه.</p><p dir="RTL"><strong>الاحتياطات عند تناول رينا اكسترا</strong></p><p dir="RTL">أبلغ الطبيب قبل تناول <strong>رينا اكسترا</strong>، إذا:</p><ul dir="rtl"><li>كانت لديك أي من الحالات المذكورة في قسم &quot;<strong>موانع تناول رينا اكسترا</strong>&quot;</li><li>كنت تعاني من مرض السكري</li><li>كنت تعاني من فرط نشاط الغدة الدرقية</li><li>كانت لديك مشاكل في البروستات</li><li>كانت لديك مشاكل في الكبد أو الكلى</li><li>كانت لديك أي حالات مرضية أخرى</li><li>كنت حاملًا أو تخططين للحمل. من غير المعروف ما إذا كان <strong>رينا اكسترا </strong>سيلحق الضرر بالجنين، لذا تحدثي مع طبيبك في هذه الحالات.</li><li>&nbsp;إذا كنت مرضع &nbsp;أو تخططين للإرضاع. &nbsp;&nbsp;من الممكن أن يعبر<strong> </strong><strong>رينا اكسترا </strong>إلى حليب الثدي. ناقشي مع طبيبك أفضل طريقة لإرضاع طفلك في حال كنت تتناولين <strong>رينا اكسترا</strong>.</li><li>&nbsp;</li></ul><p dir="RTL"><strong>الأطفال</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&nbsp;لا يستعمل <strong>رينا اكسترا </strong>للأطفال دون سن 12 عامًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التداخلات الدوائية</strong><strong> </strong><strong>من تناول </strong><strong>رينا اكسترا </strong><strong>مع أي أدوية أخرى</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>أعشاب</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>مكملات</strong><strong> </strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">أبلغ الطبيب أو الصيدلي إذا كنت تتناول &nbsp;أو تناولت مؤخرًا أو تنوي أن تتناول أدوية أخرى</p><p dir="RTL">أبلغ الطبيب عن جميع الأدوية التي تتناولها، بما في ذلك الأدوية التي تصرف بوصفة طبية وبدون وصفة طبية، الفيتامينات والمكملات العشبية.</p><p dir="RTL">قد يؤثر <strong>رينا اكسترا </strong>على الطريقة التي تعمل بها الأدوية الأخرى، وقد تؤثر الأدوية الأخرى على كيفية عمل <strong>رينا اكسترا</strong>.</p><p dir="RTL">أخبر طبيبك إذا كنت تتناول أي من هذه الأدوية بشكل خاص:</p><ul dir="rtl"><li>مثبطات الأوكسيداز أحادي الأمين (MAOIs). لا تقم بتناول <strong>رينا اكسترا </strong>خلال فترة تناول مثبطات الأوكسيداز أحادي الأمين (MAOI) أو خلال أسبوعين من التوقف عن &nbsp;تناولها.</li><li>ميثيل دوبا</li><li>ريزيربين</li><li>ديجيتاليس (ديجوكسين)</li><li>كيتوكونازول</li><li>&nbsp;إريثرومايسين</li><li>&nbsp;أزيثرومايسين</li><li>&nbsp;مضادات الهيستامين</li><li>&nbsp;مضادات الاحتقان الأخرى</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">تعرف على الأدوية التي تتناولها. احتفظ بقائمة لأدويتك وأظهرها لطبيبك والصيدلي عندما تحصل على دواء جديد.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الحمل</strong><strong> </strong><strong>والرضاعة </strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">قبل تناول <strong>رينا اكسترا </strong>عليك أن تخبري طبيبك في حال:</p><p dir="RTL">كنت حاملًا أو تخططين للحمل. من غير المعروف ما إذا كان <strong>رينا اكسترا </strong>سيلحق الضرر بالجنين. تحدثي مع طبيبك إذا كنت حاملاً أو تخططين للحمل.</p><p dir="RTL">إذا كنت مرضعة او تنوين الإرضاع. من الممكن أن يعبر <strong>رينا اكسترا </strong>إلى حليب الثدي لذا ناقشي مع طبيبك أفضل طريقة لإطعام طفلك في حال كنت تتناولين <strong>رينا اكسترا</strong>.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي</strong><strong> </strong><strong>رينا اكسترا</strong><strong> على</strong><strong> </strong><strong>الصوديوم</strong></p><p dir="RTL">يحتوي هذا الدواء على أقل من ١ ملي مول صوديوم ( ٢٣ ملغم)، وهذا يعني أنه بشكل أساسي &quot;خالٍ من الصوديوم&quot;.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">دائما تناول هذا الدواء تمامًا حسب إرشادات الطبيب أو الصيدلي إن لم تكن متأكدًا من كيفية الاستخدام، قم باستشارة طبيبك أو الصيدلي.</p><p dir="RTL">إن الجرعة الموصى بها هي قرص واحد من <strong>رينا اكسترا </strong>طويل المفعول مرتين يوميًا (كل 12 ساعة).</p><p dir="RTL">يمكن تناول <strong>رينا اكسترا </strong>مع الطعام أو بدونه.</p><p dir="RTL">قم ببلع قرص <strong>رينا اكسترا </strong>بشكل كامل. لا تقم بكسر، سحق، أو مضغ أقراص<strong> رينا اكسترا </strong>طويلة المفعول قبل بلعها. إذا لم تستطع بلع قرص <strong>رينا اكسترا </strong>كاملا، أخبر طبيبك. فقد تحتاج إلى دواء مختلف.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا نسيت أن تتناول</strong><strong> </strong><strong>رينا اكسترا</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">لا تتناول جرعة مضاعفة للتعويض عن الجرعة المنسية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى حول استخدام الدواء، اسأل الطبيب أو الصيدلي.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال في كل الأدوية، من الممكن أن يسبب <strong>رينا اكسترا </strong>أعراضًا جانبية، بالرغم من أنها قد لا تحدث لدى الجميع.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">قد يسبب <strong>رينا اكسترا </strong>أعراضًا جانبية خطيرة، بما في ذلك:</p><ul dir="rtl"><li>أعراض تؤثر على الجهاز القلبي الوعائي والجهاز العصبي المركزي، مثل:</li></ul><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم القدرة على النوم (الأرق)</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوار</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رعاش</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم انتظام ضربات القلب</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبة صرع</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم</p><ul dir="rtl"><li>يُمكن أن يزداد الشعور بالنعاس أو التعب في حال تناولت <strong>رينا اكسترا </strong>بجرعة أكبر<strong> </strong>من تلك التي أوصاك بها الطبيب.</li><li>ردود فعل تحسسية. توقف عن تناول <strong>رينا اكسترا </strong>واتصل بطبيبك على الفور أو اطلب مساعدة الطوارئ في حال ظهور أي من هذه الأعراض:</li></ul><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شرى</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الشفاه، اللسان، الوجه، والحلق</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق في التنفس أو صعوبة في التنفس</p><ul dir="rtl"><li>ردود فعل جلدية شديدة مع علامات وأعراض مثل الحمى، واحمرار الجلد، أو ظهور العديد من البثور الصغيرة.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">الأعراض الجانبية الأكثر شيوعًا عند استخدام ديسلوراتادين مع سودوإفدرين سلفات:</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم القدرة على النوم (الأرق)</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الحلق</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوار</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف في الفم</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غثيان</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعب</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نعاس</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك إذا كان لديك أي آثار جانبية تزعجك أو لا تزول.</p><p dir="RTL">لا تشمل النشرة جميع الأعراض الجانبية المحتملة&nbsp; <strong>ل</strong><strong>رينا اكسترا. </strong>لمزيد من المعلومات استشر الطبيب أو الصيدلي<strong>.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">إن كان لديك أعراضًا جانبية أو لاحظت أعراض جانبية غير مذكورة في هذه النشرة، فضلًا أبلغ الطبيب أو&nbsp; مقدم الرعاية الصحية أو الصيدلي</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ بعيدًا عن متناول أيدي الأطفال ونظرهم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم <strong>أقراص </strong><strong>رينا اكسترا </strong>بعد تاريخ الانتهاء المذكور على العبوة الخارجية. يدل تاريخ الانتهاء على آخر يوم في الشهر المذكور.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ على درجة حرارة أقل من 30 درجة مئوية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتخلص من الدواء عن طريق رميه في مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجتها. هذه الإجراءات تساعد في حماية البيئة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحتوي <strong>رينا اكسترا </strong>على ديسلوراتادين وسودوإفدرين سلفات. كل قرص <strong>رينا اكسترا </strong>طويل المفعول يحتوي على 2.5 ملغم ديسلوراتيدين و 120 ملغم سودوإفدرين سلفات.</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>المواد</strong><strong> </strong><strong>الأخرى:</strong> نشا الذرة، سيليلوز دقيق البلورية، إديتات ثنائي الصوديوم، حمض السيتريك أحادي الماء، لون أزرق (E132)، نشا مهيلم، حمض الستياريك، هيبروميلوز، بوفيدون، سيليكا غروية لا مائية، ستيارات المغنيسيوم.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما</strong><strong> </strong><strong>هو</strong><strong> </strong><strong>شكل</strong><strong> </strong><strong>رينا اكسترا ووصفه</strong> <strong>وعلى ماذا تحتوي العبوة</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">أقراص <strong>رينا اكسترا </strong>طويلة المفعول هي: أقراص بيضاوية الشكل مكونة من طبقتين، طبقة زرقاء اللون مرمزة بالرمز (C116) وطبقة أخرى ملساء بيضاء اللون.</p><p dir="RTL">أقراص<strong> رينا اكسترا </strong>طويلة المفعول<strong> </strong>متوفرة في أشرطة من الألومنيوم بحيث يحتوي كل شريط على 10 أقراص.</p><p dir="RTL"><strong>رينا اكسترا </strong>متوفر في عبوات من 10 أقراص (شريط واحد لكل عبوة)، 20 قرص (شريطين لكل عبوة)، و 30 قرص (3 أشرطة لكل عبوة).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شركة دارالدواء للتنمية والاستثمار المساهمة المحدودة</p><p dir="RTL">شارع الأمير هاشم بن الحسين</p><p dir="RTL">ناعور- عمان - الأردن</p><p dir="RTL">هاتف. 132 27 57 (6 962 +)</p><p dir="RTL">فاكس.776 27 57 (6 962 +)</p><p dir="RTL"><strong>للإبلاغ حول الأعراض الجانبية التي قد تحدث يرجى التواصل عبر العناوين التالية:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأردن</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المؤسسة العامة للغذاء والدواء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; الرقم: 962&nbsp;6&nbsp;5632000+</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: www.jfda.jo</p><p dir="RTL">رابط التبليغ: https://primaryreporting.who-umc.org/jo</p><p>البريد الإلكتروني: jpc@jfda.jo</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المملكة العربية السعودية</strong></p><table dir="rtl" border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المركز الوطني للتيقظ الدوائي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مركز الاتصال الموحد: 19999</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني <u>https://ade.sfda.gov.sa/</u>:</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإمارات العربية المتحدة</strong></p><table dir="rtl" border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قسم اليقظة الدوائية والوسائل الطبية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إدارة الدواء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وزارة الصحة ووقاية المجتمع</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الخط الساخن : ٨٠٠١١١١١</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إيميل : pv@mohap.gov.ae</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صندوق بريد: ١٨٥٣ دبي الإمارات العربية المتحدة</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السودان</strong></p><table dir="rtl" border="0" cellspacing="0" cellpadding="0" style="width:546px"><tbody><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المجلس القومي للأدوية والسموم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فاكس: &nbsp;&nbsp;183522263 (249+)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني: info@nmpb.gov.sd</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: www.nmpb.gov.sd</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدول الأخرى</strong></p><table dir="rtl" border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            01/2023
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Rina Extra 2.5 mg/120 mg Extended Release Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each extended release tablet contains Desloratadine 2.5 mg and Pseudoephedrine sulfate 120 mg. 

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Extended Release Tablets.
Bilayer, oval-shaped tablet with a blue layer coded (C116) and a white plain layer.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Seasonal Allergic Rhinitis</u></p><p>Rina Extra Extended Release Tablets are indicated for the relief of the nasal and non-nasal symptoms of seasonal allergic rhinitis, including nasal congestion, in adults and adolescents 12 years of age and older. Rina Extra Extended Release Tablets should be administered when the antihistaminic properties of desloratadine and the nasal decongestant properties of pseudoephedrine are desired (see section 5).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p><u>&nbsp;</u></p><p><em>Adults and Adolescents 12 years of Age and Over</em></p><p>The recommended dose of Rina Extra Extended Release Tablets is 1 tablet twice a day, administered approximately 12 hours apart and with or without a meal. Higher doses or increased dosing frequency of Rina Extra Extended Release Tablets have not demonstrated increased effectiveness. Do not exceed the recommended dose as desloratadine and pseudoephedrine, the active components of Rina Extra Extended Release Tablets have been associated with adverse effects at higher doses (see section 4.9).</p><p>&nbsp;</p><p><em>Pediatric population</em></p><p>The safety and efficacy of Rina Extra Extended Release Tablets in children under 12 years of age has not been established. No data available.</p><p>&nbsp;</p><p><em>Geriatric population</em></p><p>The number of subjects (n=10) &ge;65 years old treated with (Desloratadine and Pseudoephedrine sulfate combination) was too limited to make any formal statistical comparison regarding the efficacy or safety of this drug product in this age group, or to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences between the elderly and younger patients, although the elderly are more likely to have adverse reactions to sympathomimetic amines. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy (see section 5.2).</p><p>&nbsp;</p><p>Pseudoephedrine, desloratadine, and their metabolites are known to be substantially excreted by the kidney, and the risk of adverse reactions may be greater in patients with renal impairment. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor the patient for adverse events (see section 5.2).</p><p>&nbsp;</p><p><em>Renal Impairment</em></p><p>No studies with (Desloratadine and Pseudoephedrine sulfate combination) were conducted in subjects with renal impairment. (Desloratadine and Pseudoephedrine sulfate combination) should generally be avoided in patients with renal impairment (see sections 4.4 and 5.2).</p><p>&nbsp;</p><p><em>Hepatic Impairment</em></p><p>No studies with (Desloratadine and Pseudoephedrine sulfate combination) or pseudoephedrine were conducted in subjects with hepatic impairment. (Desloratadine and Pseudoephedrine sulfate combination) should generally be avoided in patients with hepatic impairment (see sections 4.4 and 5.2).</p><p>&nbsp;</p><p><em>Drug abuse and dependence</em></p><p>There is no information to indicate that abuse or dependency occurs with Desloratadine tablets alone or (Desloratadine and Pseudoephedrine sulfate combination).</p><p><u>&nbsp;</u></p><p><u>Method of administration</u></p><p><u>&nbsp;</u></p><p>Administer Rina Extra Extended Release Tablet by the oral route only. Do not break, chew, or crush the tablet. Swallow the tablet whole.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Rina Extra Extended Release Tablets are contraindicated in:
•	Patients with hypersensitivity to any of its ingredients listed in section 6.1, or to loratadine (see sections 4.4 and 4.8).
•	Patients with narrow-angle glaucoma
•	Patients with urinary retention
•	Patients receiving monoamine oxidase (MAO) inhibitor therapy or within fourteen (14) days of stopping such treatment (see section 4.5).
•	Patients with severe hypertension or severe coronary artery disease
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Cardiovascular and Central Nervous System Effects</u></p><p>The pseudoephedrine sulfate contained in Rina Extra Extended Release Tablets, like other sympathomimetic amines, can produce cardiovascular and central nervous system (CNS) effects in some patients such as insomnia, dizziness, weakness, tremor, or arrhythmias. In addition, central nervous system stimulation with convulsions or cardiovascular collapse with accompanying hypotension has been reported. Therefore, Rina Extra Extended Release Tablets should be used with caution in patients with cardiovascular disorders, and should not be used in patients with severe hypertension or severe coronary artery disease.</p><p>&nbsp;</p><p><u>Coexisting Conditions</u></p><p>Rina Extra Extended Release Tablets contain pseudoephedrine sulfate, a sympathomimetic amine, and therefore should be used with caution in patients with diabetes and hyperthyroidism. Also use with caution in patients with prostatic hypertrophy or increased intraocular pressure, as urinary retention and narrow-angle glaucoma may occur (see section 4.3).<em> </em></p><p><em>&nbsp;</em></p><p><u>Co-Administration with Monoamine Oxidase (MAO) Inhibitors</u></p><p>Rina Extra Extended Release Tablets should not be used in patients receiving monoamine oxidase (MAO) inhibitor therapy or within fourteen (14) days of stopping such treatment as an increase in blood pressure or hypertensive crisis, may occur (see sections 4.3 and 4.5).<em> </em></p><p><em>&nbsp;</em></p><p><u>Hypersensitivity Reactions</u></p><p>Hypersensitivity reactions including rash, pruritus, urticaria, edema, dyspnea, and anaphylaxis have been reported after administration of desloratadine a component of Rina Extra Extended Release Tablets. If such a reaction occurs, therapy with Rina Extra Extended Release Tablets should be stopped and alternative treatment should be considered (see section 4.8).</p><p><u>Renal Impairment</u></p><p>Rina Extra Extended Release Tablets should generally be avoided in patients with renal impairment (see section 5.2).</p><p><em>&nbsp;</em></p><p><u>Hepatic Impairment</u></p><p>Rina Extra Extended Release Tablets should generally be avoided in patients with hepatic impairment (see section 5.2).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No specific interaction studies have been conducted with (Desloratadine and Pseudoephedrine sulfate) combination.</p><p>&nbsp;</p><p><u>Monoamine Oxidase Inhibitors</u></p><p>Rina Extra should not be used in patients receiving monoamine oxidase (MAO) inhibitor therapy or within fourteen (14) days of stopping such treatment because the action of pseudoephedrine a component of Rina Extra on the vascular system may be potentiated by these agents (see sections 4.3 and 4.4).</p><p>&nbsp;</p><p><u>Beta-Adrenergic Blocking Agents</u></p><p>The antihypertensive effects of beta-adrenergic blocking agents, methyldopa, and reserpine may be reduced by sympathomimetics such as pseudoephedrine. Exercise caution when using Rina Extra with these agents.</p><p>&nbsp;</p><p><u>Digitalis</u></p><p>Increased ectopic pacemaker activity can occur when pseudoephedrine is used concomitantly with digitalis. Exercise caution when using Rina Extra with these agents.</p><p>&nbsp;</p><p><u>Inhibitors of Cytochrome P450 3A4</u></p><p>In controlled clinical studies co-administration of desloratadine with ketoconazole, erythromycin, or azithromycin resulted in increased plasma concentrations of desloratadine and 3-hydroxydesloratadine but there were no clinically relevant changes in the safety profile of desloratadine (see section 5.2).</p><p>&nbsp;</p><p><u>Fluoxetine</u></p><p>In controlled clinical studies co-administration of desloratadine with fluoxetine, a selective serotonin reuptake inhibitor (SSRI), resulted in increased plasma concentrations of desloratadine and 3-hydroxydesloratadine but there were no clinically relevant changes in the safety profile of desloratadine (see section 5.2).</p><p>&nbsp;</p><p><u>Cimetidine</u></p><p>In controlled clinical studies co-administration of desloratadine with cimetidine a histamine H2-receptor antagonist resulted in increased plasma concentrations of desloratadine and 3-hydroxydesloratadine but there were no clinically relevant changes in the safety profile of desloratadine (see section 5.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p><em>Risk Summary</em></p><p>The limited available data with (Desloratadine and Pseudoephedrine sulfate combination) in pregnant women are not sufficient to inform a drug-associated risk for major birth defects and miscarriage. There are no adequate and well-controlled studies of desloratadine and pseudoephedrine in combination in pregnant women. Neither are there animal reproduction studies conducted with the combination of desloratadine and pseudoephedrine or pseudoephedrine alone. Desloratadine given during organogenesis to pregnant rats was not teratogenic at the summed area under the concentration-time curve (AUC)-based exposures of desloratadine and its metabolite approximately 320 times that at the recommended human daily oral dose (RHD) of 5 mg/day. Desloratadine given during organogenesis to pregnant rabbits was not teratogenic at the AUC-based exposures of desloratadine approximately 230 times that at the RHD. Desloratadine given to pregnant rats during organogenesis through lactation resulted in reduced body weight and slow righting reflex of F1 pups at the summed AUC-based exposures of desloratadine and its metabolite approximately 70 times or greater than that at the <em>RHD [see Data].</em></p><p>The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.</p><p><em>Pseudoephedrine: </em></p><p>Human Data:<em> </em>The majority of studies examining the use of pseudoephedrine in pregnancy did not find an association with an increased risk of congenital anomalies. A few case-control studies conducted reported potential associations with isolated congenital disorders. However, several similar studies did not find statistically significant associations. Methodological limitations of these studies included small sample size, selection bias, recall bias, inadequate adjustment for risk factors, residual confounding, exposure misclassification, and lack of information regarding dose and timing of exposure.</p><p>Animal Data:<em> </em>No animal reproduction studies were conducted with the combination of desloratadine and pseudoephedrine or pseudoephedrine alone.</p><p><em>Desloratadine:</em></p><p>Animal Data:<em>&nbsp; </em>Desloratadine was given orally during organogenesis to pregnant rats at doses of 6, 24 and 48 mg/kg/day (approximately 50, 200 and 320 times the summed AUC-based exposure of desloratadine and its metabolite at the RHD). No fetal malformations were present. Reduced fetal weights and skeletal variations noted at doses of 24 and 48 mg/kg/day were likely secondary to the maternal toxicities of reduced body weight gain and food consumption observed at the same doses. Desloratadine was also given orally during organogenesis to pregnant rabbits at doses of 15, 30 and 60 mg/kg/day (approximately 30, 70 and 230 times the AUC-based exposure of desloratadine at the RHD). No adverse effects to the fetus were noted. Reduced maternal body weight gain was noted in rabbits at 60&nbsp;mg/kg/day. In a peri- and post-natal development study, desloratadine was given to rats orally during the peri-natal (Gestation Day 6) through lactation periods (Postpartum Day 21) at doses of 3, 9 and 18 mg/kg/day. Reduced body weight and slow righting reflex were reported in F1 pups at doses of 9 mg/kg/day or greater (approximately 70 times or greater than the summed AUC-based exposure of desloratadine and its metabolite at the RHD). Desloratadine had no effect on F1 pup development at 3 mg/kg/day (approximately 10 times the summed AUC-based exposure of desloratadine and its metabolite at the RHD). Maternal toxicities including reduced body weight gain and food consumption were noted at 18 mg/kg/day for F0 dams. F1 offspring were subsequently mated and there was no developmental toxicity for F2 pups observed.</p><p>&nbsp;</p><p><u>Lactation </u></p><p><em>Risk Summary</em></p><p>Desloratadine and pseudoephedrine both pass into breast milk. There are not sufficient data on the effects of desloratadine on the breastfed infant or the effects of desloratadine on milk production. Pseudoephedrine has been reported to decrease milk production. Pseudoephedrine has been reported to cause irritability in breastfed infants. The decision should be made whether to discontinue nursing or to discontinue (Desloratadine and Pseudoephedrine sulfate combination), taking into account the developmental and health benefits of breastfeeding, the nursing mother&rsquo;s clinical need, and any potential adverse effects on the breastfed infant from desloratadine and pseudoephedrine or from the underlying maternal condition.</p><p>&nbsp;</p><p><em>Human Data</em></p><p>Pseudoephedrine<em>: </em>In a study of eight lactating women, who were 8 to 76 weeks postpartum and received a single dose of 60 mg of pseudoephedrine, the mean 24- hour milk production was reduced by 24%. In the same study, the estimated mean relative infant dose from breast milk (assuming mean milk consumption of 150 mL/kg/day and a maternal dosing regimen of 60 mg pseudoephedrine four times per day) was calculated to be 4.3% of the weight adjusted maternal dose.</p><p><em>&nbsp;</em></p><p><em>Fertility</em></p><p>There are no data available on human infertility associated with desloratadine, pseudoephedrine, or the combination. There are no animal fertility studies with the combination or pseudoephedrine alone.</p><p>There were no clinically relevant effects of desloratadine on female fertility in rats. A male specific decrease in fertility occurred at an oral desloratadine dose of 12 mg/kg or greater in rats (approximately 65 times the summed AUC-based exposure of desloratadine and its metabolite at the RHD). Male fertility was unaffected at a desloratadine dose of 3 mg/kg (approximately 10 times the summed AUC-based exposure of desloratadine and its metabolite at the RHD). (see section 5.3).<em> </em></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>At a daily dose of 10 mg of Desloratadine were reported sedating the operation of the product. Attention and reaction time were not reduced. Similarly, it is not known that pseudoephedrine sulfate decreased psychophysical ability.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>1.1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Adverse reactions: </strong></p><p><em>&nbsp;</em></p><p>The following adverse reactions are discussed in greater detail in other sections of the label:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cardiovascular and Central Nervous System effects (see section 4.4).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased intraocular pressure (see section 4.4).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Urinary retention in patients with prostatic hypertrophy (see section 4.4).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypersensitivity reactions (see section 4.4).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe Skin Reactions</p><p><em>&nbsp;</em></p><p><strong>1.1.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Clinical Studies Experience</strong></p><p><strong>&nbsp;</strong></p><p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p><p>&nbsp;</p><p>The safety data described below are from 2 clinical trials with (Desloratadine and Pseudoephedrine sulfate combination) that included 1248 patients with seasonal allergic rhinitis, of which 414 patients received (Desloratadine and Pseudoephedrine sulfate combination) twice daily for up to 2 weeks. The majority of patients were between 18 and &lt;65 years of age with a mean age of 35.8 years and were predominantly women (64%). Patient ethnicity was 82% Caucasian, 9% Black, 6% Hispanic and 3% Asian/other ethnicity. The percentage of subjects receiving (Desloratadine and Pseudoephedrine sulfate combination) Extended Release Tablets and who discontinued from the clinical trials because of an adverse event was 3.6%. Adverse reactions that were reported by &ge;2% of subjects receiving (Desloratadine and Pseudoephedrine sulfate combination) are shown in Table 1.</p><p><em>&nbsp;</em></p><p>Table 1: Incidence of Adverse Reactions Reported by &ge;2% of Subjects Receiving (Desloratadine and Pseudoephedrine sulfate combination) Extended Release Tablets</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Adverse Reaction</strong></p></td><td style="vertical-align:top"><p><strong>(Desloratadine and Pseudoephedrine sulfate combination)</strong> <strong>BID</strong></p><p><strong>(N=414)</strong></p></td><td style="vertical-align:top"><p><strong>Desloratadine</strong></p><p><strong>5 mg QD</strong></p><p><strong>(N=412)</strong></p></td><td style="vertical-align:top"><p><strong>Pseudoephedrine</strong></p><p><strong>120 mg BID</strong></p><p><strong>(N=422)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Gastrointestinal Disorders</em></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Mouth Dry</p></td><td style="vertical-align:top"><p>8%</p></td><td style="vertical-align:top"><p>2%</p></td><td style="vertical-align:top"><p>8%</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>2%</p></td><td style="vertical-align:top"><p>1%</p></td><td style="vertical-align:top"><p>3%</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>General Disorders and Administration Site Conditions</em></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Fatigue</p></td><td style="vertical-align:top"><p>4%</p></td><td style="vertical-align:top"><p>2%</p></td><td style="vertical-align:top"><p>2%</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Metabolism and Nutrition Disorders</em></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Anorexia</p></td><td style="vertical-align:top"><p>2%</p></td><td style="vertical-align:top"><p>0%</p></td><td style="vertical-align:top"><p>2%</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Nervous System Disorders</em></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>8%</p></td><td style="vertical-align:top"><p>8%</p></td><td style="vertical-align:top"><p>9%</p></td></tr><tr><td style="vertical-align:top"><p>Somnolence</p></td><td style="vertical-align:top"><p>3%</p></td><td style="vertical-align:top"><p>4%</p></td><td style="vertical-align:top"><p>2%</p></td></tr><tr><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>3%</p></td><td style="vertical-align:top"><p>2%</p></td><td style="vertical-align:top"><p>2%</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Psychiatric Disorders</em></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Insomnia</p></td><td style="vertical-align:top"><p>10%</p></td><td style="vertical-align:top"><p>3%</p></td><td style="vertical-align:top"><p>13%</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Respiratory, Thoracic, and Mediastinal Disorders</em></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Pharyngitis</p></td><td style="vertical-align:top"><p>3%</p></td><td style="vertical-align:top"><p>3%</p></td><td style="vertical-align:top"><p>3%</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>There were no relevant differences in adverse reactions for subgroups of patients as defined by gender, age, or race.</p><p>&nbsp;</p><p><strong>1.1.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Post-marketing Experience</strong></p><p><strong>&nbsp;</strong></p><p>In addition to the adverse reactions reported during clinical trials and listed above, adverse events have been identified during post approval use of (Desloratadine and Pseudoephedrine sulfate combination). Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p><p>Adverse events identified from post-marketing surveillance on the use of (Desloratadine and Pseudoephedrine sulfate combination) include:</p><p><em>Cardiac disorders: </em>tachycardia, palpitations</p><p><em>Respiratory, thoracic and mediastinal disorders: </em>dyspnea</p><p><em>Skin and subcutaneous tissue disorders: </em>rash, pruritus</p><p>In addition to these events, the following spontaneous adverse events have been reported during the marketing of desloratadine as a single ingredient product:</p><p><em>Nervous system disorders: </em>headache, somnolence, dizziness, psychomotor hyperactivity, movement disorders (including dystonia, tics, and extrapyramidal symptoms), seizures (reported in patients with and without a known seizure disorder)</p><p><em>Immune system disorders: </em>hypersensitivity reactions (such as urticaria, edema and anaphylaxis)</p><p><em>Investigations: </em>elevated liver enzymes including bilirubin</p><p><em>Hepatobiliary disorders: </em>hepatitis</p><p><em>Metabolism and nutrition disorders: </em>increased appetite</p><p>Cases of severe skin reactions such as acute generalized exanthematous pustulosis (AGEP) have been reported with pseudoephedrine-containing products.</p><p><u>To report any side effect(s):</u></p><p><strong>Saudi Arabia: </strong></p><p>&middot;The National Pharmacovigilance Centre (NPC):</p><p>-&nbsp; SFDA Call Center: 19999</p><p>- E-mail: npc.drug@sfda.gov.sa</p><p>- Website: https://ade.sfda.gov.sa/</p><p><strong>Other GCC States:</strong></p><p><strong>&nbsp;</strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the event of overdose, consider standard measures to remove any unabsorbed drug. Symptomatic and supportive treatment is recommended. Desloratadine and 3-hydroxydesloratadine are not eliminated by hemodialysis.</p><p>&nbsp;</p><p><u>Desloratadine</u></p><p>Information regarding acute overdosage with desloratadine is limited to experience from post-marketing adverse event reports and from clinical trials conducted during the development of the (Desloratadine and Pseudoephedrine sulfate combination) product. In the reported cases of overdose, there were no significant adverse events that were attributed to desloratadine. In a dose-ranging trial, at doses of 10 mg and 20 mg/day, somnolence was reported.</p><p>In another study, no clinically relevant adverse events were reported in normal male and female volunteers who were given single daily doses of Desloratadine tablet alone 45 mg for 10 days (see section 5.1).</p><p><u>Sympathomimetics</u></p><p>In large doses, sympathomimetics such as pseudoephedrine may give rise to giddiness, headache, nausea, vomiting, sweating, thirst, tachycardia, precordial pain, palpitations, difficulty in micturition, muscle weakness and tenseness, anxiety, restlessness, and insomnia. Many patients can present a toxic psychosis with delusions and hallucinations. Some may develop cardiac arrhythmias, circulatory collapse, convulsions, coma, and respiratory failure.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Desloratadine is an Antihistamine, Pseudoephedrine sulfate is Nasal Decongestant, ATC code: R01BA52</p><p><u>Mechanism of Action</u></p><p>Desloratadine is a long acting tricyclic histamine antagonist with selective H1-receptor histamine antagonist activity. Receptor binding data indicate that at a concentration of 2 to 3 ng/mL (7 nanomolar), desloratadine shows significant interaction with the human histamine H1 receptor. Desloratadine inhibited histamine release from human mast cells <em>in vitro</em>. Results of a radiolabeled tissue distribution study in rats and a radioligand H1-receptor-binding study in guinea pigs showed that desloratadine does not readily cross the blood brain barrier. The clinical significance of this finding is unknown.</p><p>Pseudoephedrine sulfate is an orally active sympathomimetic amine and exerts a decongestant action on the nasal mucosa. Pseudoephedrine sulfate is recognized as an effective agent for the relief of nasal congestion due to allergic rhinitis. Pseudoephedrine produces peripheral effects similar to those of ephedrine and central effects similar to, but less intense than, amphetamines. It has the potential for excitatory side effects.</p><p><u>Pharmacodynamic effects</u></p><p>Wheal and Flare<strong>: </strong>Human histamine skin wheal studies following single and repeated 5 mg doses of desloratadine have shown that the drug exhibits an antihistaminic effect by 1 hour; this activity may persist for as long as 24 hours. There was no evidence of histamine-induced skin wheal tachyphylaxis within the desloratadine 5 mg group over the 28-day treatment period. The clinical relevance of histamine wheal skin testing is unknown.</p><p>Effects on QTc:<strong> </strong>In clinical trials for (Desloratadine and Pseudoephedrine sulfate combination), ECGs were recorded at baseline and endpoint within 1 to 3 hours after the last dose. The majority of ECGs were normal at both baseline and endpoint. No clinically meaningful changes were observed following treatment with (Desloratadine and Pseudoephedrine sulfate combination) for any ECG parameter, including the QTc interval. An increase in the ventricular rate of 7.1 and 6.4 bpm was observed in the (Desloratadine and Pseudoephedrine sulfate combination) and pseudoephedrine groups, respectively, compared to an increase of 3.2 bpm in subjects receiving desloratadine alone. Single daily doses of Desloratadine 45 mg were given to normal male and female volunteers for 10 days.</p><p>All ECGs obtained in this study were manually read in a blinded fashion by a cardiologist. In the Desloratadine-treated subjects, there was a mean increase in the maximum heart rate of 9.2 bpm relative to placebo. The QT interval was corrected for heart rate (QTc) by both Bazett&rsquo;s and Fridericia methods. Using the QTc (Bazett), there was a mean increase of 8.1 msec in the Desloratadine-treated subjects relative to placebo. Using QTc (Fridericia) there was a mean increase of 0.4 msec in Desloratadine-treated subjects relative to placebo. No clinically relevant adverse events were reported.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>&nbsp;In a single dose pharmacokinetic study, the mean time to maximum plasma concentrations (Tmax) for desloratadine occurred at approximately 4 to 5 hours post dose and mean peak plasma concentrations (Cmax) and area under the concentration-time curve (AUC) of approximately 1.09 ng/mL and 31.6 ng&bull;hr/mL, respectively, were observed. In another pharmacokinetic study, food and grapefruit juice had no effect on the bioavailability (Cmax and AUC) of desloratadine.</p><p>&nbsp;</p><p>For pseudoephedrine, the mean Tmax occurred at 6 to 7 hours post dose and mean peak plasma concentrations (Cmax) and area under the concentration-time curve (AUC) of approximately 263 ng/mL and 4588 ng&bull;hr/mL, respectively, were observed. Food had no effect on the bioavailability (Cmax and AUC) of pseudoephedrine.</p><p>&nbsp;</p><p>Following oral administration of (Desloratadine and Pseudoephedrine sulfate combination) twice daily for 14 days in healthy volunteers, steady-state conditions were reached on Day 10 for desloratadine, 3-hydroxydesloratadine and pseudoephedrine.</p><p>&nbsp;</p><p>For desloratadine, mean steady-state peak plasma concentrations (Cmax) and area under the concentration-time curve AUC 0-12 hrs of approximately 1.7 ng/mL and 16 ng&bull;hr/mL were observed, respectively. For pseudoephedrine, mean steady-state peak plasma concentrations (Cmax) and AUC 0-12 hrs of 459 ng/mL and 4658 ng&bull;hr/mL were observed.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>Desloratadine and 3-hydroxydesloratadine are approximately 82% to 87% and 85% to 89%, bound to plasma proteins, respectively. Protein binding of desloratadine and 3-hydroxydesloratadine was unaltered in subjects with impaired renal function.</p><p>&nbsp;</p><p><u>Metabolism</u></p><p>Desloratadine (a major metabolite of loratadine) is extensively metabolized to 3-hydroxydesloratadine, an active metabolite, which is subsequently glucuronidated. The enzyme(s) responsible for the formation of 3-hydroxydesloratadine have not been identified. Data from clinical trials with desloratadine indicate that a subset of the general population has a decreased ability to form 3-hydroxydesloratadine, and are poor metabolizers of desloratadine. In pharmacokinetic studies (n=3748), approximately 6% of subjects were poor metabolizers of desloratadine (defined as a subject with an AUC ratio of 3-hydroxydesloratadine to desloratadine less than 0.1, or a subject with a desloratadine half-life exceeding 50 hours). These pharmacokinetic studies included subjects between the ages of 2 and 70 years, including 977 subjects aged 2 to 5 years, 1575 subjects aged 6 to 11 years, and 1196 subjects aged 12 to 70 years. There was no difference in the prevalence of poor metabolizers across age groups. The frequency of poor metabolizers was higher in Blacks (17%, n=988) as compared to Caucasians (2%, n=1462) and Hispanics (2%, n=1063). The median exposure (AUC) to desloratadine in the poor metabolizers was approximately 6-fold greater than in the subjects who are not poor metabolizers. Subjects who are poor metabolizers of desloratadine cannot be prospectively identified and will be exposed to higher levels of desloratadine following dosing with the recommended dose of desloratadine. In multidose clinical safety studies, where metabolizer status was prospectively identified, a total of 94 poor metabolizers and 123 normal metabolizers were enrolled and treated with Desloratadine Syrup for 15 to 35 days. In these studies, no overall differences in safety were observed between poor metabolizers and normal metabolizers. Although not seen in these studies, an increased risk of exposure-related adverse events in patients who are poor metabolizers cannot be ruled out.</p><p>&nbsp;</p><p>Pseudoephedrine alone is incompletely metabolized (less than 1%) in the liver by N-demethylation to an inactive metabolite. The drug and its metabolite are excreted in the urine. About 55% to 96% of an administered dose of pseudoephedrine hydrochloride is excreted unchanged in the urine.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>Following single dose administration of (Desloratadine and Pseudoephedrine sulfate combination), the mean plasma elimination half-life of desloratadine was approximately 27 hours. In another study, following administration of single oral doses of desloratadine 5&nbsp;mg, Cmax and AUC values increased in a dose proportional manner following single oral doses between 5 and 20 mg. The degree of accumulation after 14 days of dosing was consistent with the half-life and dosing frequency. A human mass balance study documented a recovery of approximately 87% of the 14C-desloratadine dose, which was equally distributed in urine and feces as metabolic products. Analysis of plasma 3‑hydroxydesloratadine showed similar Tmax and halflife values compared to desloratadine.</p><p>&nbsp;</p><p>The mean elimination half-life of pseudoephedrine is dependent on urinary pH. The elimination half-life is approximately 3 to 6 or 9 to 16 hours when the urinary pH is 5 or 8, respectively.</p><p>&nbsp;</p><p><u>Geriatric Subjects</u></p><p>Following multiple-dose administration of Desloratadine tablets alone , the mean Cmax and AUC values for desloratadine were 20% greater than in younger subjects (&lt; 65 years old). The oral total body clearance (CL/F) when normalized for body weight was similar between the 2 age groups. The mean plasma elimination half-life of desloratadine was 33.7&nbsp;hr in subjects &ge;65 years old. The pharmacokinetics for 3-hydroxydesloratadine appeared unchanged in older vs. younger subjects. These age-related differences are unlikely to be clinically relevant and no dosage adjustment is recommended in elderly patients.</p><p>&nbsp;</p><p><u>Pediatric Subjects</u></p><p>(Desloratadine and Pseudoephedrine sulfate combination) are not an appropriate dosage form for use in pediatric patients below 12 years of age.</p><p>&nbsp;</p><p><u>Renally Impaired</u></p><p>Following a single dose of desloratadine 7.5 mg, pharmacokinetics were characterized in subjects with mild (n=7; creatinine clearance 51-69 mL/min/1.73 m2), moderate (n=6; creatinine clearance 34-43 mL/min/1.73 m2) and severe (n=6; creatinine clearance 5-29 mL/min/1.73 m2) renal impairment or hemodialysis dependent (n=6) subjects. In subjects with mild and moderate renal impairment, median Cmax and AUC values increased by approximately 1.2- and 1.9-fold, respectively, relative to subjects with normal renal function. In subjects with severe renal impairment or who were hemodialysis dependent, Cmax and AUC values increased by approximately 1.7- and 2.5-fold, respectively. Minimal changes in 3- hydroxydesloratadine concentrations were observed. Desloratadine and 3-hydroxydesloratadine were poorly removed by hemodialysis. Plasma protein binding of desloratadine and 3-hydroxydesloratadine was unaltered by renal impairment.</p><p>Pseudoephedrine is primarily excreted unchanged in the urine as unchanged drug with the remainder apparently being metabolized in the liver. Therefore, pseudoephedrine may accumulate in patients with renal impairment.</p><p>&nbsp;</p><p><u>Hepatically Impaired</u></p><p>Following a single oral dose of desloratadine, pharmacokinetics were characterized in subjects with mild (n=4), moderate (n=4) and severe (n=4) hepatic impairment as defined by the Child-Pugh classification of hepatic impairment and 8 subjects with normal hepatic function. Subjects with hepatic impairment, regardless of severity, had approximately a 2.4-fold increase in AUC as compared with normal subjects. The apparent oral clearance of desloratadine in subjects with mild, moderate, and severe hepatic impairment was 37%, 36%, and 28% of that in normal subjects, respectively. An increase in the mean elimination half-life of desloratadine in subjects with hepatic impairment was observed. For 3- hydroxydesloratadine, the mean Cmax and AUC values for subjects with hepatic impairment combined were not statistically significantly different from subjects with normal hepatic function.</p><p>&nbsp;</p><p><u>Gender</u></p><p>Female subjects treated for 14 days with Desloratadine tablets alone had 10% and 3% higher desloratadine Cmax and AUC values, respectively, compared with male subjects. The 3-hydroxydesloratadine Cmax and AUC values were also increased by 45% and 48%, respectively, in females compared with males. However, these apparent differences are not considered to be clinically relevant.</p><p>&nbsp;</p><p><u>Race</u></p><p>Following 14 days of treatment with Desloratadine tablets alone, the Cmax and AUC values for desloratadine were 18% and 32% higher, respectively in Blacks compared with Caucasians. For 3-hydroxydesloratadine there was a corresponding 10% reduction in Cmax and AUC values in Blacks compared to Caucasians. These differences are not considered to be clinically relevant.</p><p>&nbsp;</p><p><u>Drug Interaction</u></p><p>In 2 controlled crossover clinical pharmacology studies in healthy male (n=12 in each study) and female (n=12 in each study) subjects, desloratadine 7.5 mg (1.5 times the daily dose) once daily was co-administered with erythromycin 500 mg every 8 hours or ketoconazole 200 mg every 12 hours for 10 days. In 3 separate controlled, parallel group clinical pharmacology studies, desloratadine at the clinical dose of 5 mg has been co-administered with azithromycin 500 mg followed by 250 mg once daily for 4 days (n=18) or with fluoxetine 20 mg once daily for 7 days after a 23-day pretreatment period with fluoxetine (n=18) or with cimetidine 600 mg every 12 hours for 14 days (n=18) under steady state conditions to healthy male and female subjects. Although increased plasma concentrations (Cmax and AUC 0-24 hrs) of desloratadine and 3-hydroxydesloratadine were observed (see Table 2), there were no clinically relevant changes in the safety profile of desloratadine, as assessed by electrocardiographic parameters (including the corrected QT interval), clinical laboratory tests, vital signs and adverse events.</p><p>&nbsp;</p><p><strong>Table 2: Changes in Desloratadine and 3-hydroxydesloratadine Pharmacokinetics in Healthy Male and Female Subjects</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Desloratadine</strong></p><p><strong>&nbsp;</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>3-hydroxydesloratadine</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>C<sub>max</sub></strong></p></td><td style="vertical-align:top"><p><strong>AUC<sub> 0-24hrs</sub></strong></p></td><td style="vertical-align:top"><p><strong>C<sub>max</sub></strong></p></td><td style="vertical-align:top"><p><strong>AUC <sub>0-24hrs</sub></strong></p></td></tr><tr><td style="vertical-align:top"><p>Erythromycin</p><p>(500 mg Q8h)</p></td><td style="vertical-align:top"><p>+24%</p></td><td style="vertical-align:top"><p>+14%</p></td><td style="vertical-align:top"><p>+43%</p></td><td style="vertical-align:top"><p>+40%</p></td></tr><tr><td style="vertical-align:top"><p>Ketoconazole</p><p>(200 mg Q12h)</p></td><td style="vertical-align:top"><p>+45%</p></td><td style="vertical-align:top"><p>+39%</p></td><td style="vertical-align:top"><p>+43%</p></td><td style="vertical-align:top"><p>+72%</p></td></tr><tr><td style="vertical-align:top"><p>Azithromycin</p><p>(500 mg Day 1,</p><p>250 mg QD x 4 days)</p></td><td style="vertical-align:top"><p>+15%</p></td><td style="vertical-align:top"><p>+5%</p></td><td style="vertical-align:top"><p>+15%</p></td><td style="vertical-align:top"><p>+4%</p></td></tr><tr><td style="vertical-align:top"><p>Fluoxetine</p><p>(20 mg QD)</p></td><td style="vertical-align:top"><p>+15%</p></td><td style="vertical-align:top"><p>+0%</p></td><td style="vertical-align:top"><p>+17%</p></td><td style="vertical-align:top"><p>+13%</p></td></tr><tr><td style="vertical-align:top"><p>Cimetidine</p><p>(600 mg Q12h)</p></td><td style="vertical-align:top"><p>+12%</p></td><td style="vertical-align:top"><p>+19%</p></td><td style="vertical-align:top"><p>-11%</p></td><td style="vertical-align:top"><p>-3%</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Carcinogenesis, Mutagenesis, Impairment of Fertility</u></p><p>There are no animal or laboratory studies on the combination product of desloratadine and pseudoephedrine sulfate or pseudoephedrine alone to evaluate carcinogenesis, mutagenesis, or impairment of fertility.</p><p>&nbsp;</p><p><em>Carcinogenicity Studies</em></p><p><em>Desloratadine</em></p><p>The carcinogenic potential of desloratadine was assessed using a loratadine study in rats and a desloratadine study in mice. In a 2-year study in rats, loratadine was administered in the diet at doses up to 25 mg/kg/day (approximately 45 times the summed AUC-based exposure of desloratadine and its metabolite at the RHD). A significantly higher incidence of hepatocellular tumors (combined adenomas and carcinomas) was observed in males given 10 mg/kg/day of loratadine (approximately 10 times the summed AUC-based exposure of desloratadine and its metabolite at the RHD) and in males and females given 25 mg/kg/day of loratadine. The clinical significance of these findings during long-term use of desloratadine is not known. In a 2-year dietary study in mice, males and females given up to 16 mg/kg/day and 32 mg/kg/day desloratadine, respectively (approximately 30 and 70 times</p><p>&nbsp;</p><p>the summed AUC-based exposure of desloratadine and its metabolite at the RHD, respectively), did not show significant increases in the incidence of any tumors.</p><p><em>Pseudoephedrine</em></p><p>The carcinogenic potential of pseudoephedrine was assessed using ephedrine sulfate studies in F344/N rats and B6C3F1 mice conducted under the National Toxicology Program (NTP). In a 2-year dietary study in rats, male and female rats given up to 9 and 11 mg/kg/day ephedrine sulfate (approximately 0.4 and 0.5 times the RHD of 240 mg/day on a mg/m2 basis, respectively) did not show any evidence of tumorigenicity. In a 2-year dietary study in mice, male and female mice given up to 29 and 25 mg/kg/day ephedrine sulfate (approximately 0.7 and 0.6 times the RHD of pseudoephedrine on a mg/m2 basis, respectively) did not show any evidence of tumorigenicity.</p><p>&nbsp;</p><p><em>Genotoxicity Studies</em></p><p>Desloratadine</p><p>In genotoxicity studies with desloratadine, there was no evidence of genotoxic potential in a reverse mutation assay (<em>Salmonella/E. coli </em>mammalian microsome bacterial mutagenicity assay) or in 2 assays for chromosomal aberrations (human peripheral blood lymphocyte clastogenicity assay and mouse bone marrow micronucleus assay).</p><p>Pseudoephedrine</p><p>Mutagenicity studies with pseudoephedrine have not been conducted.</p><p>&nbsp;</p><p><em>Impairment of Fertility</em></p><p>Desloratadine</p><p>In a female fertility study, desloratadine was given to female rats orally 14 days prior to and throughout mating until Gestation Day 7 at doses of 6, 12 and 24 mg/kg/day. An increase in preimplantation loss and a decrease in number of implantations and fetuses noted at 24 mg/kg (approximately 200 times the summed AUC-based exposure of desloratadine and its metabolite at the RHD) was likely due to maternal toxicities including reduced body weight gain and food consumption. In a male fertility study in rats, desloratadine was given orally to male rats for 70 days prior to mating and throughout the mating period (total dosing period 106-108 days) at doses of 3, 12 and 40 mg/kg/day. Reduced body weight gain, food consumption, and absolute organ weights of testes, epididymis, and cauda epididymis were noted at 40 mg/kg/day. A male-specific decrease in fertility, demonstrated by reduced female conception rates, decreased sperm numbers and motility, and histopathologic changes in testes and epididymis, occurred at a dose of 12 mg/kg or greater (approximately 65 times or greater than the summed AUC-based exposure of desloratadine and its metabolite at the RHD). Desloratadine had no effect on male fertility in rats at 3 mg/kg/day (approximately 10 times the summed AUC-based exposure of desloratadine and its metabolite at the RHD).</p><p>Pseudoephedrine</p><p>Fertility studies with pseudoephedrine have not been conducted.</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Maize starch, microcrystalline cellulose, disodium edetate, citric acid monohydrate, indigo carmine (E132), pregelatinized starch, stearic acid, hypromellose, povidone, colloidal anhydrous silica, and magnesium stearate.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months  
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Rina Extra Extended Release Tablets are packed in aluminum blisters of 10s.</p><p>Rina Extra is available in packs of 10 extended release tablets (1 blister per pack), 20 extended release tablets (2 blisters per pack), and in packs of 30 extended release tablets (3 blisters per pack).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Dar Al Dawa Development & Investment Co Ltd 
Prince Hashem Bin Al-Hussein Street.
Na'ur – Amman – Jordan.  
Tel. (+962 6) 57 27 132
Fax. (+962 6) 57 27 776

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                01/11/2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>